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Introduction
Cancer of the prostate is the neoplasm with the highest in-
cidence in the United States, although not the neoplasm
with the highest mortality, as seen in Table I. This has
been taken from the year 2001 American Cancer Society
Cancer Facts & Figures publication [1] for comparisons
between cancers of the prostate, lung & bronchus and
colon & rectum. In the same publication [1] it is estimated
that there will be 198,1000 new cases of prostate cancer in
the USA in 2001 and an estimated 31,5000 deaths. The
comparable estimates, for males and females combined,
for cancer of the lung and bronchus are respectively
169,500 new cases and 157,400 deaths.
Etiology
Relatively little is known about the etiology of prostate
cancer, although the data on the black population of Afri-
ca and the USA provides some evidence of a genetic com-
ponent to prostate cancer risk, the geographical and tem-
poral variations and the results of migrant studies indica-
te that life-style comprises a large fraction of the causes of
prostate cancer [2]. At all ages, African-American men
are more likely than whites to develop prostate cancer
but cancer incidence rates have increased for both Ame-
rican white and African-American men with the rates for
the latter rising from 106 per 100,000 in 1973 to 234 per
100,000 in 1994 [3].
Incidence rates vary among racial and ethnic groups
and Table II shows the rates in the USA for the different
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Table I. Incidence and mortality in males in the USA 1990-97 by site
and race [1]. The rates are per 100,000 population age-adjusted 
to the 1970 USA standard population. The incidence data
is from the 11 SEER (Surveillance, Epidemiology 
and End Results program) 
areas and the mortality data is from all states
Site White population Black population
Incidence Mortality Incidence Mortality
Prostate 145.8 23.3 225.0 54.1
Lung & bronchus 71.9 69.5 111.1 99.5
Colon & rectum 52.7 21.3 58.3 27.7
Scentific Consultant, South Croydon, United Kingdom
Table II. Prostate cancer age-adjusted 
incidence rates per 100,000 males, USA 1988-92,
by race and ethnicity [3]
Race/ethnicity Incidence rate
African-American 180.6
White 134.7
Hispanic 89.0
Japanese 88.0
Filipino 69.8
Hawaiian 57.2
American-Indian 52.5
Alaska Natives 46.1
Chinese 46.0
Vietnamese 40.0
Korean 24.2
Asian-American populations. The highest rate is for Japa-
nese-Americans and the lowest for Korean-Americans [3].
Sex hormones have also been implicated in the etio-
logy of this cancer, primarily on the basis that the growth
and development of the prostate gland requires the pre-
sence of sex hormones. It has been reported [3] that men
with high plasma testerostone levels may be at an incre-
ased risk of developing prostate cancer. However, the
hormonal hypothesis has received only equivocal support
from epidemiological studies and clinical observations.
Prostatic cancer mortality rates are associated with mari-
tal status, increasing in the following order: single, mar-
ried, widowed, divorced [2].
Some studies have shown an overall twofold to thre-
efold increase in the risk of prostate cancer in men with
a positive family history. The number of affected family
relatives and younger age at diagnosis appear to be influ-
ential familial factors [3] and strong familial pre-disposi-
tion may be responsible for some 5-10% of prostate can-
cers [1].
Diet has also been suggested as a risk factor with
a diet high in animal fat approximately doubling the risk.
Alternatively, the consumption of lycopene, an antioxi-
dant found in tomatoes and tomato-based products may
be associated with a decreased risk [3].
Other risk factors which have been studied but which
have failed to show any statistically significant correla-
tion with the incidence of prostate cancer, include ionising
radiation, socioeconomic status, benign prostatic hyperpla-
sia, vasectomy, smoking and farming & agricultural work [4-
-9]. As well as farming, occupational risks have also been
studied from chronic exposure to cadmium oxide dust
over a period of 10 or more years [10] but the results are
conflicting.
To conclude this short summary on etiology the follo-
wing statement is reproduced from a discussion [11] on la-
tent disease versus clinically manifest disease. 'The projec-
ted lifetime risk of developing histologic evidence of can-
cer of the prostate in a 50 year old man is 42%, of the
clinical disease 9.5% and of dying from the disease is
2.9%'.
Age-Standardised & Crude Incidence Rates
The pattern of occurrence of prostate cancer is not simi-
lar in all countries. Figure 1 is reproduced from an IARC
publication in 1990 on Patterns of Cancer in Five Conti-
nents [12] where the age-standardised incidence rates per
100,000 population are ranked from highest to lowest
with the maximum and minimum rates at the base of the
bar chart: 91.2 for the black population of Atlanta, USA
and 1.2 for Tianjin in the Peoples' Republic of China.
The population used for the standardisation is the 'world'
population: not the 1970 US standard population used
for the incidence rates in Table I. However, the ratio of
Mortality/Incidence for black and white US populations
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Figure 1. Age-standardised incidence rates per 100,000 population for selected populations in five continents [12]. Courtesy IARC.
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Table III. Crude incidence rates per 100,000 males for selected populations, the age-standardised rate per 100,000 (ASR) and the percentage of all
cancers which are prostate cancer [13]. When the absolute numbers of registered prostate cancer cases are small, the standard errors associated
with the rate per 100,000 will be large. It should also be noted that not all cancer registries outside north America and Europe are as efficient and
comprehensive as those for example in the USA, and there may be a significant element of missed registrations. Nevertheless, this IARC
publication [13] gives the best available incidence estimates towards the end of the 20th century. Notation: *Skin other than Kaposi's sarcoma or
melanoma is not considered: ICD 9th 173. **Includes all skin.
Table IIIa. Africa and Central & South America
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Africa
Setif, Algeria 12 1990-93 0.5 1.8 1.2 Bronchus, lung
Bamako, Mali 33 1988-92 2.0 0.5 3.3 Liver
Kyadondo, Uganda 86 1991-93 5.7 27.7 7.9 Kaposi's sarcoma
Harare, African, 112 1990-92 6.9 29.2 7.0 Kaposi's sarcoma
Zimbabwe
Central & South America
Concordia, Argentina 48 1990-94 14.1 16.2 6.8 Bronchus, lung
Belem, Brazil 145 1989-91 7.6 17.9 8.2 Stomach
Goiania, Brazil 291 1990-93 16.5 35.2 15.2 Prostate
Porto Allegre, Brazil 566 1990-92 32.0 42.8 12.2 Bronchus, lung
Cali, Colombia 693 1987-91 19.8 32.7 15.9 Stomach
Costa Rica 1179 1988-92 15.5 27.0 13.0 Stomach
Quito, Ecuador 386 1988-92 13.5 22.4 14.6 Stomach
Lima, Peru 767 1990-91 12.7 19.4 14.5 Stomach
Puerto Rico, USA 4831 1988-91 72.2 54.7 28.1 Prostate
Montevideo, Uruguay 939 1990-92 49.4 32.6 11.5 Bronchus, lung
Table IIIb. North America
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Canada
All Canada 59546 1988-92 86.6 64.7 21.5 Prostate
Ontario 21472 1988-92 84.4 63.0 20.6 Prostate
Saskatchewan 2857 1988-92 112.7 66.8 25.6 Prostate
USA White Populations
All SEER Registries 66227 1988-92 142.2 100.8 29.0 Prostate
Los Angeles County 14961 1988-92 167.5 96.3 28.4 Prostate
San Francisco Bay Area 8194 1988-92 153.7 95.9 25.3 Prostate
Connecticut 9189 1988-92 128.8 79.1 24.4 Prostate
USA Black Populations
All SEER Registries 7129 1988-92 116.6 137.0 30.1 Prostate
Los Angeles County 2865 1988-92 116.1 130.6 30.3 Prostate
Atlanta 1235 1988-92 79.6 142.3 28.7 Prostate
Detroit 3397 1988-92 158.1 141.5 32.3 Prostate
Table IIIc. Asia
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Asia
Shanghai, China 530 1988-92 2.9 2.3 1.0 Bronchus, lung
Hong Kong 1185 1988-92 8.1 7.9 2.5 Bronchus, lung
Bombay, India 764 1988-92 2.9 7.9 4.1 Bronchus, lung
Hiroshima, Japan 329 1986-90 12.6 10.9 3.4 Stomach
Osaka Prefecture Japan 1758 1988-92 8.2 6.8 2.5 Stomach
Kangwha County, Korea 3 1986-92 1.2 0.9 0.5 Stomach
Manila, Philippines 632 1988-92 5.9 17.6 5.9 Bronchus, lung
Singapore-Chinese 415 1988-92 7.8 9.8 3.7 Bronchus, lung
Chiang Mai, Thailand 122 1988-92 3.5 4.1 2.6 Bronchus, lung
Hanoi, Vietnam 24 1991-93 0.8 1.2 0.7 Bronchus, lung
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Figure 2. Incidence and mortality rates per 100,000 population, by race
and five-year age group, USA 1990-94. [3]. These rates are age-adju-
sted to the 1970 US standard population. The data source is the NCI, Su-
rveillance, Epidemiology, and End Results Program, 1997. Courtesy
American Cancer Society.
Figure 3. Incidence and mortality rates per 100,000 population, by race
and registration year, USA 1973-94. [3]. These rates are age-adjusted to
the 1970 US standard population. The data source is the NCI, Surveillan-
ce, Epidemiology, and End Results Program, 1997. Courtesy American
Cancer Society.
Table IIId. Europe: Eastern & Western. Notation: The six states are Berlin, Brandenburg, Mecklenburg-Vorpommern, 
Sachsen-Anhalt, Sachsen and Thuringen
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Eastern Europe
Belarus 3049 1988-92 12.8 12.2 4.6 Bronchus, lung
Czech Republic 8481 1988-92 33.8 24.1 8.6 Bronchus, lung
Estonia 931 1988-92 25.5 21.6 8.1 Bronchus, lung
Latvia 1185 1988-92 19.2 15.8 6.9 Bronchus, lung
Cracow, Poland 266 1988-92 14.9 13.4 5.2 Bronchus, lung
Western Europe
Somme, France 779 1988-92 58.1 36.5 14.0 Bronchus, lung
6 States, Germany 5017 1988-89 31.5 23.7 10.0 Bronchus, lung
Southern Ireland 631 1988-92 47.4 30.4 15.3 Bronchus, lung
Florence, Italy 1231 1988-91 54.9 24.4 9.4 Bronchus, lung
The Netherlands 17659 1989-92 59.5 39.6 15.2 Bronchus, lung
Asturias, Spain 720 1988-91 34.0 18.1 7.5 Bronchus, lung
Basel, Switzerland 1008 1988-92 97.3 50.3 20.9 Prostate
England & Wales, UK 38317 1988-90 51.6 28.0 12.3 Bronchus, lung
Table IIIe. Europe: Scandinavia
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Scandinavia
Denmark 7392 1988-92 58.3 31.0 13.5 Bronchus, lung
Finland 8559 1987-92 59.0 41.3 17.7 Bronchus, lung
Iceland 529 1988-92 82.8 61.0 24.7 Prostate
Norway 10014 1988-92 95.4 48.4 22.7 Prostate
Sweden 25253 1988-92 119.5 55.3 27.1 Prostate
Table IIIf. Australia & New Zealand
Population Total cases Period Crude rate ASR % of all Cancer with the
registered of registration cancers** highest ASR incidence*
Australia
New South Wales 10870 1988-92 74.8 53.5 18.2 Prostate
South Australia 2904 1988-92 81.5 53.6 18.4 Prostate
Victoria 7086 1988-92 65.4 47.6 16.8 Prostate
Western Australia 2534 1988-92 62.8 52.8 17.8 Prostate
New Zealand
Non-Maori 4192 1988-92 55.6 37.8 14.6 Bronchus, lung
Maori 135 1988-92 17.3 44.4 9.1 Bronchus, lung
are of the same order of magnitude, 1.54 in Table I [1]
and 1.95 in Figure 1 for Atlanta/Connecticut.
The crude incidence rates per 100,000 males for se-
lected populations in the 1997 IARC publication on Can-
cer Incidence in Five Continents [13] are given in Table
III. The highest rates are observed amongst the USA
black population, see also Figure 1, and the lowest rates in
the countries of south-east Asia. It should also be noted
that the incidence of prostate cancer is increasing in ma-
ny European countries [2].
Age-Specific Incidence Rates
Age is the single most important risk factor for the deve-
lopment of prostate cancer [3] with this cancer being ve-
ry rare before the age of 50 years. Figures 2 and 3 compa-
res incidence and mortality rates for the African-Ameri-
can and USA white populations by five-year age group
and by year. Figure 4 shows USA incidence and mortali-
ty rates by race and ethnicity. Figure 5 compares age-
-specific incidence rates for selected populations in north
and south America, eastern Europe and Asia.
Acknowledgements
I am grateful to Dr T.H.P. Tai for helpful discussions and
to the IARC and the American Cancer Society for per-
mission to publish Figures 1-4.
Richard F. Mould MSc, PhD
41, Ewhurst Avenue
South Croydon
Surrey CR2 0DH
United Kingdom
e-mail: richardfmould@hotmail.com
References
1. American Cancer Society. Cancer facts and figures 2001. Atlanta: ACS;
2001.
2. Smans M, Muir CS, Boyle P, eds. Atlas of cancer mortality in the European
Economic Community. IARC Scientific publication no. 107, Lyon: Inter-
national Agency for Research on Cancer, 1992.
3. American Cancer Society. Cancer facts and figures 1998. Special section:
prostate cancer. Atlanta: ACS; 1998.
4. Baba S. Epidemiology of cancer of the prostate: analysis of countries of
high and low incidence. In: Jacobi GH, Hohenfellner R, eds. Prostate
cancer. International perspectives in urology. Vol. 3. Baltimore: Williams &
Wilkin;, 1982, p. 11-28.
5. Brawley OW, Kramer BS. Epidemiology of prostate cancer. In: Vogelzang
NJ, Scardino PT, Shipley WU, et al. eds. Comprehensive textbook of geni-
tourinary medicine. Baltimore: Williams & Wilkins; 1996, p. 565-572.
6. Gallagher RP. Recent developments in the epidemiology of prostate can-
cer. Can J Urol 116; 3:14-9.
7. Pienta KJ, Epidemiology and etiology and prostate cancer. In: Raghaven
D, Scher HI, Leibel SA, et al. eds. Principles and practice of genitourinary
oncology. Philadelphia: Lippincott-Raven; 1996, p. 379-411.
8. Platz EA, Kantoff PW, Giovannucci E, eds. Epidemiology of and risk
factors for protate cancer. In: Klein EA, ed. Management of prostate can-
cer. Totowa: Humana Press, 2000; p.19-45.
9. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D, Fraumeni
JF, eds. Cancer epidemiology and prevention, 2nd edn. Oxford: Oxford Uni-
versity Press, 1996, p.1180-205.
10. Hirayama T, Waterhouse JAH, Fraumeni JF, eds. Cancer risks by site.
IARC Technical report series. Vol. 41, Geneva: International Agency for
Research on Cancer, 1980, p. 150-151.
11. Abeloff MD, Armitage JO, Lichter AS, et al, eds. Clinical oncology. New
York: Churchill Livingstone; 1995, p. 1440.
12. Whelan SL, Parkin DM, Masuyer E, eds. Patterns of cancer in five conti-
nents. IARC Scientific publication no. 102, Lyon: International Agency for
Research on Cancer, 1990.
13. Parkin DM, Whelan SL, Ferlay J, et al, eds. Cancer incidence in five con-
tinents. Vol. 7. IARC Scientific publication no. 143, Lyon: International
Agency for Research on Cancer, 1997.
Accepted: 28 August 2001
15
Figure 4. Incidence and mortality rates per 100,000 population, by race
and ethnicity, USA 1988-92. [3]. These rates are age-adjusted to the
1970 US standard population. The data source is the NCI, Surveillance,
Epidemiology, and End Results Program, 1997. Courtesy American Can-
cer Society.
Figure 5. Age-specific incidence rates per 100,000 population for six se-
lected countries, drawn using rates in the data tables in Cancer Inciden-
ce in Five Continents Volume VII [13]. These are the SEER USA black
and white populations and that of all Canada (see Table IIIb), Cali, Co-
lombia (see Table IIIa), Lativa (see Table IIId) and Hong Kong (see Ta-
ble IIIc). They form a representative spectrum of incidence rates with
age-standardised rates (ASR) in the range 137.0 to 7.9 and for example
for age 80 years, the age-specific incidence for the USA black population
is some 2000 per 100,000 whereas for Hong Kong it is a factor of 10 times
lower at 200 per 100,000 males. At age 60 years the differences are even
greater, 600 per 100,000 compared to only 20 per 100,000.
